Objective: To examine evidence that speci®c ®bre-associated macronutrients are associated with a decreased breast cancer risk. To review possible mechanisms, the age group when dietary intervention might be most effective and the choice of a suitable dietary supplement. Design: This review distinguishes speci®c hormone-metabolic effects of dietary composition from those of body mass and fat distribution, in relation to the age at which they exert major effects on breast cancer risk. Results: Both obesity and a high-fat/low-®bre diet in Western women may be associated with increased estrogen levels which are widely assumed to increase the risk of developing breast cancer. Both obesity and the Western diet are likely to stimulate insulin resistance, leading to increased levels of bioavailable estrogen. The concomitants of hyperinsulinemia may synergize with estrogen in stimulating progression of pre-neoplastic lesions in the breasts of late pre-menopausal women. Increased intake of ®bre-associated macronutrients may reduce insulin resistance in addition to reducing the circulating levels of estrogen. Conclusions: The effect of dietary intervention on breast cancer risk in Western women may be tested in premenopausal women over the age of 40 y, with evidence of atypical hyperplasia in a breast biopsy. The most suitable ®bre-associated macronutrient is still problematical but soy protein constituents have been shown to inhibit the growth of rat mammary cancer models and also of human breast cancer cell lines in the laboratory.
Introduction
International correlation between dietary fat content and breast cancer mortality rates has led to the longstanding hypothesis that a fat-rich diet may increase breast cancer risk. However, only a weak positive correlation is shown in most case-control and prospective studies on the association between dietary fat content in adult life and breast cancer risk (Willett, 1989) . Currently, multicenter trials in the USA (Chlebowski, 1995) and Canada (Boyd et al, 1995) are testing the effect on breast cancer risk of reducing dietary fat intake to 15±20% of total energy intake. Pessimism has been expressed, especially after the recent publication of a pooled analysis of seven prospective studies in four countries (4980 cases in 337 819 women aged between 28 and 93 y). The report (Hunter et al, 1996) concluded that in the context of the Western lifestyle, lowering the total intake of fat in midlife is unlikely to substantially reduce the risk of breast cancer.
Dietary composition exerts its major effect on breast cancer risk in three age groups; (1) in childhood when rich nutrition favors earlier onset of menarche; (2) in late premenopause when progression of precursor lesions may be modulated by hormone-metabolic changes associated with speci®c dietary macronutrients; (3) after the menopause when further progression in these lesions may be favored by hormone-metabolic changes associated with excess adiposity.
A widely-quoted hypothesis is that the effect of nutrition on breast cancer incidence is mediated mainly through an effect on age at menarche, weight and height (De Waard et al, 1977; Gray et al, 1979) , and estrogen is assumed to have a major role in mammary carcinogenesis. But dietary constituents may also have a direct hormone-metabolic effect on estrogen and insulin levels. Insulin resistance and hyperinsulinemia have been shown as signi®cant risk markers for breast cancer in a large case-control study (Bruning et al, 1992) and the authors suggest that it may be a metabolic link between the rich diet of Western populations and their high incidence of breast cancer in women.
Multiple studies show that both pre-and post-menopausal Western women have higher circulating and excretion levels of total estrogens, estrone and estradial than do lowrisk Asian women (Bernstein & Ross, 1993) . In the case of postmenopausal women, higher mean body weight in Western women may account for some of the difference, as adipose tissue is the major site of aromatization of androgen to estrogen after the menopause. The reason for the lower estrogen levels in pre-menopausal Asian women is not clear but recent research relates it to the high ®breafat ratio in their diet (Adlercreutz et al, 1992) .
With regard to individual risk of breast cancer, multiple studies in Western and Asian populations have shown only small differences in estrogen levels between cases and controls. It is possible that small variations within the normal range may promote mammary carcinogenesis or else that metabolites by the 16-a-hydroxylated pathway may be involved (Bradlow et al, 1986) . Most authorities however, assume that a higher free estradiol level is a major determinant of breast cancer risk in women (Bennett & Ingram, 1990) and that it may be a consequence of a lowered level of sex hormone-binding globulin (SHBG).
This review distinguishes speci®c hormone-metabolic effects of dietary composition from those of body mass and fat distribution, in relation to the age at which they are most likely to exert major effects on cancer risk. It is postulated that the incidence of post-menopausal breast cancer may be reduced by dietary supplements of speci®c ®bre-associated macronutrients, best started about 10 y before the menopause.
Putative role of body mass
Earlier onset of menarche is a risk marker for breast cancer. Mean age of girls at menarche has advanced from 16±13 y in Western women since the beginning of the century and has been related to improved nutrition. Height also is reported to be a risk marker for breast cancer and in this respect, height may be a marker of childhood energy intake, as children who experience energy deprivation fail to attain their full potential height. Variations in energy intake in prepubertal children are likely to explain some of the variation internationally in breast cancer incidence (Stoll, 1995a) .
Present evidence suggests that nutrition in¯uences the onset of menarche by promoting accumulation of adipose tissue rather than through the intake of speci®c macronutrients. Studies in the USA and Canada (Maclure et al, 1991; Moisan et al, 1990) have noted that earlier than average menarche is associated with greater height and weight and that after allowing for these variables, no association was found with energy-adjusted intake of fat, protein or carbohydrate. The reason for an increased breast cancer risk associated with earlier menarche is not clear. Some suggest that it in¯uences subsequent ovarian hormone levels but an alternative explanation is that the longer interval between menarche and ®rst birth permits more DNA mutations in rapidly proliferating mammary epithelial cells. Menarche might be delayed by avoiding or reducing obesity, combined with regular physical exercise in prepubertal girls (Frazier et al, 1995) .
With regard to adult Western women, practically all studies report an association between higher body mass and increased breast cancer risk in post-menopausal women but a modestly decreased risk in pre-menopausal women (Radimer & Bain, 1995) . Some studies stress that this difference is related more to age than to menstrual status (Tretli, 1989 ) so that risk is decreased by obesity at the age of 35 y but gradually evolves to an increased risk by the age of 55 y. On this basis, the difference in risk with age may be related to the changing distribution of body fat in women as they get older.
Body fat accumulation in women under the age of 40 y is mainly on the hips and thighs (gynoid obesity), but after the age of 40 y it tends to become more abdominal (android obesity) especially in Western women (Ballard-Barbash, 1994) . Abdominal obesity may manifest in geneticallypredisposed women following rapid weight gain, leading to hyperinsulinemic insulin resistance (Kohrt et al, 1993) . However, insulin levels generally increase progressively after the age of 40 y in Western women and this may be unrelated to weight gain (Wing et al, 1992) . The next section examines the evidence that the development of such insulin resistance is likely to be stimulated by the Western high fat/low ®bre diet.
The promotion of post-menopausal breast cancer by obesity is likely to begin at an early pre-menopausal age.
A recent study in 318 breast cancer patients, 80% of them post-menopausal, reports breast cancer risk to be related mainly to weight gain which begins and persists after the age of 30 y (Kumar et al, 1996) . Similar ®ndings were noted in a recent review of the timing of weight gain in relation to breast cancer risk (Stoll, 1995b) . Decreased SHBG levels associated with increased free estradiol levels are found in nearly all obese women (Haffner et al, 1988; Haffner et al, 1992) but in the case of obese premenopausal women, free estradiol levels are higher in the presence of abdominal than of lower body obesity (Kirschner et al, 1990) . Abdominal obesity may be occult in some women and is more reliably demonstrated by imaging (CAT or MRI) than by measurement of the waist-hip circumference ratio (de Ridder et al, 1992) .
The above evidence suggests that the concomitants of obesity, especially abdominal obesity, may promote mammary carcinogenesis. Although associated with decreased risk of pre-menopausal breast cancer, obesity beginning and persisting after the age of 30 y is associated with increased risk of post-menopausal breast cancer. In postmenopausal women, the presence of obesity is associated not only with an increased risk of breast cancer but also with evidence of a poorer prognosis. Obesity should therefore be reduced and avoided in all age groups as a means of reducing breast cancer risk.
Putative role of dietary composition
A protective effect from high dietary ®bre intake against breast cancer risk is increasingly suggested by case-control studies from many countries (Kolonel et al, 1981; Lubin et al, 1986; Brisson et al, 1989; Pryor et al, 1989; Iscovich et al, 1989; Van't Veer et al, 1990; Lee et al, 1991; Graham et al, 1991; Zaridze et al, 1991; Levi et al, 1993; Rohan et al, 1993; Trichopoulou et al, 1995; Yuan et al, 1995) . It is not con®rmed in two large prospective studies in the USA (Kushi et al, 1992; Willett et al, 1992) but it is possible that differences in the speci®c types of dietary ®bre is associated with decreased risk of epithelial hyperplasia, a precursor of breast cancer.
There is substantial evidence that some types of dietary ®bre can reduce blood estrogen levels (Adlercreutz, 1990; Rose, 1993) . Vegetarians generally show lower plasma estradiol levels and higher SHBG levels in post-menopausal women than do non-vegetarians (Bernstein & Ross, 1993) and an inverse correlation has been shown between estradiol levels and dietary ®bre intake both in pre-and post-menopausal women (Barbosa et al, 1990; Goldin et al, 1982; Adlercreutz et al, 1987) . The mechanism may involve change in the enterohepatic cycling of estrogen or an effect through lignans and iso¯avonoid compounds with antiestrogenic properties (Adlercreutz, 1990; Rose, 1993) but in addition, ®bre-associated macronutrients may correct hyperinsulinemia in women with insulin resistance (Stoll, 1996) . This may lead to increased SHBG levels and decreased levels of bioavailable estrogen.
The fat-rich Western diet favors the development of insulin resistance while diets rich in ®bre and carbohydrates have the opposite effect (Smith, 1994) . When normoglycemic subjects were changed to a high-®bre, high-carbohydrate diet combined with regular aerobic exercise, they showed reduction of insulin levels (Barnard et al, 1992; Hellenius et al, 1995) . Such change was not found in earlier reports (Borkman et al, 1991) , but as noted above, the type of ®bre intake may determine insulin response.
The presence of hyperinsulinemic insulin resistance in women has been correlated with increased breast cancer risk in a large case-control study (Bruning et al, 1992) . Apart from increasing free estradiol levels, hyperinsulinemic insulin resistance may promote breast cancer development by an additional mechanism (Stoll, 1996) . Insulin has long been known to be an important growth factor for human mammary cancer cells in vitro but its growthpromoting effect in vivo is likely to be through the insulin-like growth factors IGF1 and IGF11 (Arteaga & Osborne, 1989) . Synergism has been shown between estradiol and IGF in stimulating the growth of the MCF7 human breast cancer cell (Stewart et al, 1990; Thorsen et al, 1992) .
Dietary intervention studies are the only reliable method of establishing a link between dietary constituents and circulating estrogen levels. Change from a meat-eating to a vegetarian diet by premenopausal women was associated with reduction of estradiol levels in one study (Bennett & Ingram, 1990) and similar results were noted in three studies of pre-menopausal women put on to a high ®brea low fat diet (Bagga et al, 1995) . Finally, supplements of wheat bran (but not of oat or corn bran) were shown to reduce estradiol levels in premenopausal women without any change in fat consumption (Rose et al, 1991) .
Recent research on vegetable products showing anticarcinogenic effects have focused on soy protein. It is a major dietary component in Japan and China where the incidence of breast cancer is about one-®fth of that in Caucasian women. A Japanese prospective study noted an inverse relationship between intake of soybean curd or miso soup and the risk of breast cancer, and another showed a protective effect from soyabean paste soup (Cassidy et al, 1995) . A case-control study of Chinese women in Singapore found an inverse association between breast cancer risk in pre-menopausal women and soy protein intake (Lee et al, 1991) although another study in China showed no association (Yuan et al, 1995) . Soy extracts show antiproliferative effects on tumor growth in a variety of animal tumors including mammary, prostate and colon cancers (Barnes, 1995) . Genistein has been found the most active of soy constituents in this respect although other components such as phytic acid and protease inhibitors are also active.
Genistein at high concentration inhibits the growth of estrogen receptor-positive MCF7 human breast cancer cells in vitro, although at lower concentrations, growth is stimulated (Wang et al, 1996) . It is thought to compete with estradiol for binding to estrogen receptors, and prolonged exposure decreases the response of the cancer cells to estrogen stimulation (Wang et al, 1996; Hoffman, 1995) . Genistein at high concentration also inhibits the growth of estrogen receptor-negative MCF7 cells (Wang et al, 1996) and genistein's antioxidant properties may contribute to its anticarcinogenic effects in receptor-negative cells (Wei et al, 1995) . A recent study in premenopausal women found that administration of soy milk supplement of over 200 mg iso¯avone daily for one month caused reduction of serum estradiol levels which persisted for two to three months after soy was withdrawn (Lu et al, 1996) . On the other hand, a previous study reported that soy supplement of only 45 mg iso¯avone daily caused a rise in estradiol levels in premenopausal women (Cassidy et al, 1995) .
It is likely that the majority of postmenopausal breast cancers originate before the menopause (Simpson et al, 1988) and if diet-related, hormone-metabolic changes are involved in their promotion, dietary intervention trials need to begin in the pre-menopause. The development of breast cancer is though to involve several steps in tumor promotion and the ®nding of atypical hyperplasis in a breast biopsy suggests that a precursor stage has been reached at one or more foci. There is however, evidence that some precursor lesions may regress spontaneously when involutionary changes begin in breast tissue in Western women usually around the age of 40 y. It is reported that atypical hyperplasia is most common between the ages of 36 and 40 y and that its frequency falls steadily thereafter (Simpson et al, 1982) . Also that the incidence of ductal carcinoma in situ (DCJS) in mastectomy specimens is much reduced after the menopause (Nielsen et al, 1984) .
It has been suggested that estrogenic stimulation of involuting breast tissue is likely to inhibit this trend to spontaneous regression of atypical hyperplasia and DCJS lesions (Henson & Tarone, 1994) . The hypothesis may explain observations that pregnancy after the age of 35 y increases breast cancer risk even in multiparae (Trichopoulos et al, 1983; Kalache et al, 1993) . It is reported that all cells of atypical hyperplasia and DCJS lesions are estrogen receptor-positive (Nenci et al, 1988) , and therefore capable of being stimulated by raised levels of estrogen. All these ®ndings suggest that hormone-metabolic intervention aiming to reduce the incidence of post-menopausal breast cancer is most likely to be successful if started well before the menopause.
Conclusions
Pre-menopausal women showing atypical hyperplasia on breast biopsy could be enrolled in a randomized trial of a speci®c ®bre-associated macronutrient given as a dietary supplement. Possible mechanisms may be clari®ed by serial monitoring of circulating levels of estrogen, androgen, insulin and SHBG, in addition to serial measurement of body weight and body fat distribution. Such women have a risk ratio of 2±4 compared to average, and are likely to be highly motivated and compliant with long term dietary supplements. The use of a precursor lesion as a starting point for dietary intervention means that follow-up over relatively few years may be suf®cient to show any bene®t from the supplement.
There is at present insuf®cient evidence on the optimal dietary supplement. While insoluble ®bre such as wheat bran is thought to reduce reabsorption of estrogen from the bowel (Rose et al, 1991) , rice ®bre may improve insulin sensitivity (Gates et al, 1996) leading to decrease in bioavailable estrogen levels. Soya protein is a rich source of iso¯avones with antiestrogenic properties. In the Western diet, soy is increasingly found in chocolate, cooking oils, milk drinks, mayonnaise, pasta, sausage, breakfast cereals and convenience foods, but Western intake of iso¯avones is still less than 5 mg d compared to 25± 50 mg in Asia (Lu et al, 1996) . Various soy preparations are suitable for supplementary feeding and this makes it a prime candidate for pilot trials aiming at the reduction of breast cancer .
